Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney disease
Aim. To assess renal artery stenting (RAS) effectiveness and safety in patients with renovascular hypertension (RVH) duration over 10 years.Material and methods. Seventy-eight patients were randomized into main (n=26) and placebo groups (n=52). Primary end-point was systolic blood pressure (SBP) lev...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2008-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1561 |
| _version_ | 1797882698984849408 |
|---|---|
| author | A. N. Kharlamov Ya. L. Gabinsky M. S. Freydlina E. K. Bos T. A. Naydanova S. D. Chernyshev B. V. Fadin |
| author_facet | A. N. Kharlamov Ya. L. Gabinsky M. S. Freydlina E. K. Bos T. A. Naydanova S. D. Chernyshev B. V. Fadin |
| author_sort | A. N. Kharlamov |
| collection | DOAJ |
| description | Aim. To assess renal artery stenting (RAS) effectiveness and safety in patients with renovascular hypertension (RVH) duration over 10 years.Material and methods. Seventy-eight patients were randomized into main (n=26) and placebo groups (n=52). Primary end-point was systolic blood pressure (SBP) level. Secondary end-points included: restenosis incidence; glomerular filtration rate (GFR); effective renal plasma flow (ERPF); creatinine level and microalbuminuria (MAU); quality of life (QoL); renal biopsy and immuno-hystochemical assay data; renal vessel calcification; cerebral metabolism level.Results. RAS resulted in average BP decrease from 181/107 to 142/93 mm Hg; after 6 weeks, no patient achieved target BP levels. Restenosis at 12 months was observed in 17% of the patients from both groups; another RAS was needed in 8%. According to dynamic nephroscintigraphy results, GFR reduced by 5% (p<0,05), and ERPF - by 3% (p<0,05). Creatinine level decreased by 3% (p<0,01), and MAU - by 7% (p<0,05). Assessed by SF-36 questionnaire, QoL was normal in 14- 29% only.Conclusion. RAS remains an ineffective method of RVH treatment, even though it prevents renal artery thrombosis and improves RVH control to some extent. |
| first_indexed | 2024-04-10T03:39:55Z |
| format | Article |
| id | doaj.art-d0c8e6f127594340835703e08a67530a |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:39:55Z |
| publishDate | 2008-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-d0c8e6f127594340835703e08a67530a2023-03-13T07:23:15Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252008-08-017483881278Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney diseaseA. N. Kharlamov0Ya. L. Gabinsky1M. S. Freydlina2E. K. Bos3T. A. Naydanova4S. D. Chernyshev5B. V. Fadin6Клинико-диагностический центр “Кардиология”, г. ЕкатеринбургКлинико-диагностический центр “Кардиология”, г. ЕкатеринбургКлинико-диагностический центр “Кардиология”, г. ЕкатеринбургМедицинский центр Университета Гронинген, г. ГронингенЦентр сердца и сосудов Свердловской областной клинической больницы №1, г. ЕкатеринбургЦентр сердца и сосудов Свердловской областной клинической больницы №1, г. ЕкатеринбургЦентр сердца и сосудов Свердловской областной клинической больницы №1, г. ЕкатеринбургAim. To assess renal artery stenting (RAS) effectiveness and safety in patients with renovascular hypertension (RVH) duration over 10 years.Material and methods. Seventy-eight patients were randomized into main (n=26) and placebo groups (n=52). Primary end-point was systolic blood pressure (SBP) level. Secondary end-points included: restenosis incidence; glomerular filtration rate (GFR); effective renal plasma flow (ERPF); creatinine level and microalbuminuria (MAU); quality of life (QoL); renal biopsy and immuno-hystochemical assay data; renal vessel calcification; cerebral metabolism level.Results. RAS resulted in average BP decrease from 181/107 to 142/93 mm Hg; after 6 weeks, no patient achieved target BP levels. Restenosis at 12 months was observed in 17% of the patients from both groups; another RAS was needed in 8%. According to dynamic nephroscintigraphy results, GFR reduced by 5% (p<0,05), and ERPF - by 3% (p<0,05). Creatinine level decreased by 3% (p<0,01), and MAU - by 7% (p<0,05). Assessed by SF-36 questionnaire, QoL was normal in 14- 29% only.Conclusion. RAS remains an ineffective method of RVH treatment, even though it prevents renal artery thrombosis and improves RVH control to some extent.https://cardiovascular.elpub.ru/jour/article/view/1561ишемическая болезнь почекреноваскулярная гипертониястентирование почечных артерий |
| spellingShingle | A. N. Kharlamov Ya. L. Gabinsky M. S. Freydlina E. K. Bos T. A. Naydanova S. D. Chernyshev B. V. Fadin Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney disease Кардиоваскулярная терапия и профилактика ишемическая болезнь почек реноваскулярная гипертония стентирование почечных артерий |
| title | Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney disease |
| title_full | Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney disease |
| title_fullStr | Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney disease |
| title_full_unstemmed | Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney disease |
| title_short | Stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension Part 1. Effectiveness and safety of renal artery stenting in ischemic kidney disease |
| title_sort | stenting and cell technologies in the treatment of atherosclerotic renovascular hypertension part 1 effectiveness and safety of renal artery stenting in ischemic kidney disease |
| topic | ишемическая болезнь почек реноваскулярная гипертония стентирование почечных артерий |
| url | https://cardiovascular.elpub.ru/jour/article/view/1561 |
| work_keys_str_mv | AT ankharlamov stentingandcelltechnologiesinthetreatmentofatheroscleroticrenovascularhypertensionpart1effectivenessandsafetyofrenalarterystentinginischemickidneydisease AT yalgabinsky stentingandcelltechnologiesinthetreatmentofatheroscleroticrenovascularhypertensionpart1effectivenessandsafetyofrenalarterystentinginischemickidneydisease AT msfreydlina stentingandcelltechnologiesinthetreatmentofatheroscleroticrenovascularhypertensionpart1effectivenessandsafetyofrenalarterystentinginischemickidneydisease AT ekbos stentingandcelltechnologiesinthetreatmentofatheroscleroticrenovascularhypertensionpart1effectivenessandsafetyofrenalarterystentinginischemickidneydisease AT tanaydanova stentingandcelltechnologiesinthetreatmentofatheroscleroticrenovascularhypertensionpart1effectivenessandsafetyofrenalarterystentinginischemickidneydisease AT sdchernyshev stentingandcelltechnologiesinthetreatmentofatheroscleroticrenovascularhypertensionpart1effectivenessandsafetyofrenalarterystentinginischemickidneydisease AT bvfadin stentingandcelltechnologiesinthetreatmentofatheroscleroticrenovascularhypertensionpart1effectivenessandsafetyofrenalarterystentinginischemickidneydisease |